Targeted News Service

New TREMFYA(r) (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
October 13, 2026

NEW BRUNSWICK, New Jersey, Oct. 13 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

New TREMFYA(r) (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

*

Spring House, Pa. (October 12, 2026) - Johnson & Johnson today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA(r) (guselkumab) across . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form